整形科

订阅

MedSci主页 / 所有栏目 / 整形科

热烈庆祝吉适研究壁报在IMCAS Asia大会

2022-01-27 高德美研习社 网络

吉适IMCAS Asia
关注

热烈庆祝吉适研究壁报在IMCAS Asia大会

 

 

 

​

END

CN-DYS-2100071

材料仅供医疗卫生专业人士学习交流

不作为临床使用推荐及其他用途

相关临床应用应符合中国国家药品监督管理局批准的使用说明书

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780123, encodeId=868c1e80123a4, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Feb 23 04:26:37 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624984, encodeId=f38716249840d, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Jan 29 08:26:37 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188732, encodeId=0ec51188e32bf, content=热烈祝贺！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Fri Jan 28 04:05:09 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
    2022-02-23 luwei00

    #ASIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1780123, encodeId=868c1e80123a4, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Feb 23 04:26:37 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624984, encodeId=f38716249840d, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Jan 29 08:26:37 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188732, encodeId=0ec51188e32bf, content=热烈祝贺！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Fri Jan 28 04:05:09 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
    2022-01-29 yaanren

    #Cas#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1780123, encodeId=868c1e80123a4, content=<a href='/topic/show?id=10d62860dd' target=_blank style='color:#2F92EE;'>#ASIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2860, encryptionId=10d62860dd, topicName=ASIA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Wed Feb 23 04:26:37 CST 2022, time=2022-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1624984, encodeId=f38716249840d, content=<a href='/topic/show?id=0333412062' target=_blank style='color:#2F92EE;'>#Cas#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4120, encryptionId=0333412062, topicName=Cas)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=411420689333, createdName=yaanren, createdTime=Sat Jan 29 08:26:37 CST 2022, time=2022-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188732, encodeId=0ec51188e32bf, content=热烈祝贺！, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=58001397990, createdName=yx1156, createdTime=Fri Jan 28 04:05:09 CST 2022, time=2022-01-28, status=1, ipAttribution=)]
    2022-01-28 yx1156

    热烈祝贺！

    0

相关资讯

指南共识：Dysport吉适面部美学注射中的实际实用：上面部与中面部

肉毒毒素自20世纪70年代开始使用。在第一次用于斜视和几种很难治疗的神经疾病后，肉毒毒素已经形成了微创美容面部治疗的基础。

热烈庆祝吉适研究壁报在IMCAS Asia大会

本资料旨在向且仅向医疗专业人士提供科学信息。如果您不是医疗专业人士,请勿阅读或传播其中的内容。

指南共识：Dysport吉适面部美学注射中的实际实用：下面部